Total Payments
$63,039
2024 Payments
$57,268
Companies
12
Transactions
69
Medicare Patients
841
Medicare Billing
$107,335
Payment Breakdown by Category
Consulting$57,250 (90.8%)
Other$4,089 (6.5%)
Food & Beverage$1,483 (2.4%)
Education$217.04 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $57,250 | 4 | 90.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,089 | 3 | 6.5% |
| Food and Beverage | $1,483 | 59 | 2.4% |
| Education | $217.04 | 3 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| XTANT MEDICAL INC | $57,250 | 4 | $0 (2024) |
| F. Hoffmann-La Roche AG | $4,089 | 3 | $0 (2019) |
| Astellas Pharma US Inc | $437.80 | 9 | $0 (2018) |
| Melinta Therapeutics, Inc. | $400.59 | 13 | $0 (2018) |
| ViiV Healthcare Company | $248.26 | 18 | $0 (2017) |
| Allergan Inc. | $204.48 | 9 | $0 (2018) |
| The Medicines Company | $117.31 | 5 | $0 (2017) |
| BOSTON SCIENTIFIC CORPORATION | $113.33 | 1 | $0 (2021) |
| United Therapeutics Corporation | $83.99 | 1 | $0 (2017) |
| Merck Sharp & Dohme LLC | $60.51 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,268 | 5 | XTANT MEDICAL INC ($57,250) |
| 2021 | $113.33 | 1 | BOSTON SCIENTIFIC CORPORATION ($113.33) |
| 2019 | $3,268 | 2 | F. Hoffmann-La Roche AG ($3,268) |
| 2018 | $1,329 | 20 | F. Hoffmann-La Roche AG ($821.37) |
| 2017 | $1,061 | 41 | Astellas Pharma US Inc ($393.23) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | XTANT MEDICAL INC | — | Consulting Fee | Cash or cash equivalent | $21,050.00 | General |
| 11/20/2024 | XTANT MEDICAL INC | — | Consulting Fee | Cash or cash equivalent | $19,250.00 | General |
| 10/30/2024 | XTANT MEDICAL INC | — | Consulting Fee | Cash or cash equivalent | $7,750.00 | General |
| 09/18/2024 | XTANT MEDICAL INC | — | Consulting Fee | Cash or cash equivalent | $9,200.00 | General |
| 05/16/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/06/2021 | BOSTON SCIENTIFIC CORPORATION | Superion (Device) | Food and Beverage | In-kind items and services | $113.33 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | Tamiflu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $618.66 | General |
| Category: Virology & Specialty Care | ||||||
| 06/30/2019 | F. Hoffmann-La Roche AG | Tamiflu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,649.07 | General |
| Category: Virology & Specialty Care | ||||||
| 10/30/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/17/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/15/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/12/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/28/2018 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), PREVYMIS, DIFICID | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/21/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/10/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | Cash or cash equivalent | $120.31 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/06/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $28.87 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/02/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 06/30/2018 | F. Hoffmann-La Roche AG | Tamiflu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $821.37 | General |
| Category: Virology & Specialty Care | ||||||
| 06/08/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/23/2018 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 04/21/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/16/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/10/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 03/02/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug) | Food and Beverage | In-kind items and services | $28.02 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 02/20/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug) | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: INFECTIOUS DISEASES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 75 | 84 | $22,665 | $6,536 |
| 2022 | 3 | 159 | 231 | $66,053 | $18,484 |
| 2021 | 4 | 172 | 251 | $78,269 | $21,329 |
| 2020 | 5 | 435 | 699 | $200,054 | $60,987 |
Total Patients
841
Total Services
1,265
Medicare Billing
$107,335
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 26 | $8,136 | $2,554 | 31.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 30 | $7,025 | $1,922 | 27.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $5,970 | $1,532 | 25.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 13 | $1,534 | $527.67 | 34.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 86 | 148 | $46,614 | $13,118 | 28.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 60 | 70 | $15,370 | $4,228 | 27.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 13 | $4,069 | $1,138 | 28.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 95 | 167 | $53,106 | $14,523 | 27.3% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 40 | 43 | $13,459 | $3,561 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 28 | $6,244 | $1,715 | 27.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 13 | $5,460 | $1,530 | 28.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 181 | 371 | $117,979 | $35,927 | 30.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 96 | 153 | $34,117 | $10,244 | 30.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 97 | 99 | $30,987 | $9,676 | 31.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 26 | 26 | $10,920 | $3,245 | 29.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 35 | 50 | $6,050 | $1,895 | 31.3% |
About Dr. Sally Alrabaa, MD
Dr. Sally Alrabaa, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912071994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sally Alrabaa, MD has received a total of $63,039 in payments from pharmaceutical and medical device companies, with $57,268 received in 2024. These payments were reported across 69 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($57,250).
As a Medicare-enrolled provider, Alrabaa has provided services to 841 Medicare beneficiaries, totaling 1,265 services with total Medicare billing of $107,335. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease, Internal Medicine
- Location Tampa, FL
- Active Since 11/20/2006
- Last Updated 03/30/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1912071994
Products in Payments
- Tamiflu (Drug) $4,089
- Baxdela (Drug) $345.07
- TRIUMEQ (Drug) $203.99
- Cresemba (Drug) $194.28
- AVYCAZ (Drug) $148.09
- MINOCIN IV (Drug) $117.31
- Superion (Device) $113.33
- Vabomere (Drug) $55.52
- CRESEMBA (Drug) $44.57
- TIVICAY (Drug) $44.27
- TEFLARO (Drug) $40.30
- PREZCOBIX (Drug) $18.58
- PREVYMIS (Drug) $18.09
- NOXAFIL (Drug) $18.05
- DALVANCE (Drug) $16.09
- VIBATIV (Drug) $14.98
- ZERBAXA (Drug) $13.54
- DIFICID (Drug) $10.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Internal Medicine $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Internal Medicine $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Internal Medicine $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Internal Medicine $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357
Internal Medicine $273,357